Barclays Sticks to Their Hold Rating for Moderna (MRNA)
Barclays analyst Eliana Merle maintained a Hold rating on Moderna today and set a price target of $48.00.
Claim 55% Off TipRanks
- Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis.
- Discover high-conviction stock picks and new investing opportunities with the TipRanks Smart Investor Newsletter
According to TipRanks, Merle is a 3-star analyst with an average return of 1.4% and a 36.58% success rate. Merle covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, Alnylam Pharma, and PTC Therapeutics.
In addition to Barclays, Moderna also received a Hold from UBS’s Michael Yee in a report issued yesterday. However, on the same day, Bank of America Securities maintained a Sell rating on Moderna (NASDAQ: MRNA).
Based on Moderna’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $389 million and a GAAP net loss of $1.34 billion. In comparison, last year the company earned a revenue of $107 million and had a GAAP net loss of $971 million
Based on the recent corporate insider activity of 50 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of MRNA in relation to earlier this year. Last month, Noubar Afeyan, a Director at MRNA sold 9,263.00 shares for a total of $433,878.92.
Read More on MRNA:
Disclaimer & DisclosureReport an Issue
- FDA issues draft guidance to help accelerated cell, gene therapies for patients
- Moderna, Merck to present 5-year data for intismeran autogene
- Moderna expands pact with CEPI to advance potential vaccine against BDBV
- Moderna Advances mRNA Lyme Disease Vaccine Into Phase 2: What Investors Should Watch
- JPMorgan, Chevron, Strategy, Moderna, Snap Insider Shake-Up
